Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | AGER | Q15109 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787655 | 1.00 | CYP19A1 (0.36) | CYP19A1LSSACSS2OPRD1TOP2A | |
| SCHEMBL7666687 | 0.87 | GRM5 (0.34) | ACSS2TSHR | |
| SCHEMBL2202154 | 0.87 | CYP11B1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL2744999 | 0.84 | SLC22A12 (0.34) | CYP19A1ACSS2TOP2ATOP2BMEN1 | |
| SCHEMBL5688715 | 0.83 | SIRT2 (0.40) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL2914446 | 0.83 | HTT (0.36) | CYP19A1ACSS2PHGDH | |
| SCHEMBL8147915 | 0.82 | FNTA (0.36) | CYP19A1ACSS2 | |
| SCHEMBL8147914 | 0.82 | FNTA (0.36) | CYP19A1ACSS2 | |
| SCHEMBL845130 | 0.82 | CYP11B1 (0.43) | CYP19A1OPRD1MEN1KMT2ACYP11B1 | |
| SCHEMBL7191177 | 0.82 | S1PR3 (0.35) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691859-B2 | Prenyl transferase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2010-04-06 | — | — | US | disclosed |
| EP-1382607-B1 | Prenyl transferase inhibitors | IPSEN PHARMA (FR) | 2009-08-19 | — | — | EP | disclosed |
| US-20080176835-A1 | Prenyl Transferase Inhibitors | BIOMEASURE, INCORPORATED | 2008-07-24 | — | — | US | disclosed |
| US-7361656-B2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2008-04-22 | — | — | US | disclosed |
| US-7084135-B1 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2006-08-01 | — | — | US | disclosed |
| EP-1140942-B1 | PRENYL TRANSFERASE INHIBITORS | CONSEILS DE RECH SET D APPLIC (FR) | 2004-03-10 | — | — | EP | disclosed |
| EP-1382607-A2 | Prenyl transferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-01-21 | — | — | EP | disclosed |
| EP-1140942-A2 | PRENYL TRANSFERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039130-A2 | PRENYL TRANSFERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2000-07-06 | — | — | WO | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176835-A1 | Prenyl Transferase Inhibitors | FNTA, FNTB, RCE1 | CYP19A1 2162/4885LSS 176/4885ACSS2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.